Tag Archives: VIVO

Ortho Clinical Diagnostics (NASDAQ:OCDX) & Meridian Bioscience (NASDAQ:VIVO) Financial Analysis

Ortho Clinical Diagnostics (NASDAQ:OCDX) and Meridian Bioscience (NASDAQ:VIVO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Profitability

Get Ortho Clinical Diagnostics alerts:

This table compares Ortho Clinical Diagnostics and Meridian Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ortho Clinical Diagnostics N/A -117.10% 3.21%
Meridian Bioscience 23.29% 24.58% 16.60%

Analyst Recommendations

This is a breakdown of current ratings for Ortho Clinical Diagnostics and Meridian Bioscience, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ortho Clinical Diagnostics 0 1 11 0 2.92
Meridian Bioscience 0 0 2 0 3.00

Ortho Clinical Diagnostics currently has a consensus target price of $25.36, suggesting a potential upside of 25.01%. Meridian Bioscience has a consensus target price of $30.50, suggesting a potential upside of 56.01%. Given Meridian Bioscience’s stronger consensus rating and higher probable upside, analysts clearly believe Meridian Bioscience is more favorable than Ortho Clinical Diagnostics.

Insider & Institutional Ownership

92.2% of Meridian Bioscience shares are owned by institutional investors. 2.0% of Meridian Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Ortho Clinical Diagnostics and Meridian Bioscience’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ortho Clinical Diagnostics $1.77 billion 2.56 -$211.90 million $0.29 69.97
Meridian Bioscience $253.67 million 3.34 $46.19 million $1.07 18.27

Meridian Bioscience has lower revenue, but higher earnings than Ortho Clinical Diagnostics. Meridian Bioscience is trading at a lower price-to-earnings ratio than Ortho Clinical Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

Meridian Bioscience beats Ortho Clinical Diagnostics on 10 of the 13 factors compared between the two stocks.

About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.

About Meridian Bioscience

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products; and sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Top Stocks To Own Right Now

Media coverage about Robert Half International (NYSE:RHI) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Robert Half International earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave media coverage about the business services provider an impact score of 46.3338192078073 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Top Stocks To Own Right Now: Meridian Bioscience Inc.(VIVO)

Advisors’ Opinion:

  • [By Logan Wallace]

    VIVO (CURRENCY:VIVO) traded up 1.3% against the dollar during the 1 day period ending at 22:00 PM Eastern on September 23rd. VIVO has a market cap of $299,503.00 and $1,152.00 worth of VIVO was traded on exchanges in the last 24 hours. Over the last seven days, VIVO has traded down 0.9% against the dollar. One VIVO coin can now be bought for about $0.11 or 0.00001625 BTC on major cryptocurrency exchanges including Stocks.Exchange, CryptoBridge and Cryptopia.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Motley Fool Transcribing]

    Meridian Bioscience (NASDAQ:VIVO) Q1 2019 Earnings Conference CallJan. 24, 2019 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Logan Wallace]

    Intellia Therapeutics (NASDAQ: NTLA) and Meridian Bioscience (NASDAQ:VIVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    ILLEGAL ACTIVITY WARNING: “Meridian Bioscience, Inc. (VIVO) Holdings Reduced by Louisiana State Employees Retirement System” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at www.tickerreport.com/banking-finance/4129405/meridian-bioscience-inc-vivo-holdings-reduced-by-louisiana-state-employees-retirement-system.html.

Top Stocks To Own Right Now: LookSmart Ltd.(LOOK)

Advisors’ Opinion:

  • [By Shane Hupp]

    Peel Hunt reissued their buy rating on shares of Lookers (LON:LOOK) in a research note issued to investors on Wednesday morning.

    A number of other equities analysts also recently weighed in on the stock. Numis Securities reaffirmed a buy rating and issued a GBX 130 ($1.76) price target on shares of Lookers in a research note on Wednesday, March 7th. JPMorgan Chase upped their price target on shares of Lookers from GBX 109 ($1.48) to GBX 130 ($1.76) and gave the stock an overweight rating in a research note on Thursday, March 8th. Liberum Capital reaffirmed a buy rating and issued a GBX 145 ($1.97) price target on shares of Lookers in a research note on Wednesday, March 7th. Finally, Canaccord Genuity reaffirmed a buy rating and issued a GBX 146 ($1.98) price target on shares of Lookers in a research note on Monday, March 5th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Lookers has an average rating of Buy and an average price target of GBX 137.71 ($1.87).

  • [By Stephan Byrd]

    Lookers (LON:LOOK)‘s stock had its “buy” rating restated by investment analysts at Peel Hunt in a note issued to investors on Friday.

Top Stocks To Own Right Now: Eaton Vance Municipal Income 2028 Term Trust(ETX )

Advisors’ Opinion:

  • [By Max Byerly]

    Etrion SA (TSE:ETX) – Equities researchers at National Bank Financial issued their Q4 2018 earnings estimates for shares of Etrion in a research note issued on Thursday, August 9th. National Bank Financial analyst R. Merer expects that the solar energy provider will post earnings of ($0.01) per share for the quarter. National Bank Financial also issued estimates for Etrion’s FY2019 earnings at ($0.01) EPS.

Best Value Stocks To Invest In Right Now

New York, NY, based Investment company Standard General L.P. buys Turning Point Brands Inc during the 3-months ended 2018-03-31, according to the most recent filings of the investment company, Standard General L.P.. As of 2018-03-31, Standard General L.P. owns 4 stocks with a total value of $89 million. These are the details of the buys and sells.

Added Positions: NCMI, TPB,

For the details of Standard General L.P.’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Standard+General+L.P.

These are the top 5 holdings of Standard General L.P.National CineMedia Inc (NCMI) – 14,387,113 shares, 83.65% of the total portfolio. Shares added by 8.59%Turning Point Brands Inc (TPB) – 455,319 shares, 9.92% of the total portfolio. Shares added by 49.13%CafePress Inc (PRSS) – 2,500,000 shares, 3.77% of the total portfolio. Emmis Communications Corp (EMMS) – 515,231 shares, 2.66% of the total portfolio. Added: Turning Point Brands Inc (TPB)

Standard General L.P. added to a holding in Turning Point Brands Inc by 49.13%. The purchase prices were between $19.44 and $22.38, with an estimated average price of $21.12. The stock is now traded at around $25.96. The impact to a portfolio due to this purchase was 3.27%. The holding were 455,319 shares as of 2018-03-31.

Best Value Stocks To Invest In Right Now: Meridian Bioscience Inc.(VIVO)

Advisors’ Opinion:

  • [By Logan Wallace]

    VIVO (CURRENCY:VIVO) traded down 0.1% against the dollar during the 24 hour period ending at 0:00 AM Eastern on May 8th. In the last seven days, VIVO has traded down 9.4% against the dollar. One VIVO coin can now be bought for about $0.77 or 0.00008506 BTC on major cryptocurrency exchanges including Cryptopia, CryptoBridge and Stocks.Exchange. VIVO has a market cap of $1.41 million and approximately $9,560.00 worth of VIVO was traded on exchanges in the last day.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Intellia Therapeutics (NASDAQ: NTLA) and Meridian Bioscience (NASDAQ:VIVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Best Value Stocks To Invest In Right Now: Franklin Financial Network, Inc.(FSB)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Franklin Financial Network (FSB)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lee Jackson]

    Franklin Financial Network Inc. (NYSE: FSB) was downgraded to sell from neutral at Compass Point. The stock has traded in a 52-week range of $30.30 to $42.65. The consensus price target for the company across Wall Street is $37.80. The stock closed Monday at $39.40, a rise of more than 5%.

  • [By Stephan Byrd]

    ValuEngine lowered shares of Franklin Financial Network (NYSE:FSB) from a hold rating to a sell rating in a research report sent to investors on Monday.

  • [By Max Byerly]

    Franklin Financial Network (NYSE:FSB) was downgraded by research analysts at Compass Point from a “neutral” rating to a “sell” rating in a research note issued on Tuesday, The Fly reports.

Best Value Stocks To Invest In Right Now: Blackrock Health Sciences Trust(BME)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Shares of B&M European Value Retail SA (LON:BME) have earned an average recommendation of “Buy” from the sixteen ratings firms that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is GBX 442.92 ($5.90).

  • [By Max Byerly]

    B&M European Value Retail (LON:BME) had its target price boosted by analysts at HSBC from GBX 470 ($6.26) to GBX 500 ($6.66) in a report released on Wednesday. The brokerage presently has a “buy” rating on the stock. HSBC’s price objective indicates a potential upside of 21.54% from the company’s current price.

Best Value Stocks To Invest In Right Now: Finisar Corporation(FNSR)

Advisors’ Opinion:

  • [By Anders Bylund]

    Finisar(NASDAQ:FNSR) followed in AAOI’s footsteps in March, surging more than 10% higher around the announcement of Lumentum’s Oclaro deal, but losing it all amid deafening radio silence. By the end of March, the stock had fallen 12.2% lower, and Finisar has not enjoyed any glowing analyst analyses in April.

  • [By Ezra Schwarzbaum]

    Finisar Corporation (NASDAQ: FNSR) was up 2.9 percent Monday morning. The stock had fallen 4 percent on the Commerce Department news in April.

    Several other optics stocks stand to gain. In a Monday note, Bank of America Merrill Lynch analyst Vivek Arya also highlighlited the semiconductor space as one that could benefit from the news. Other stocks to watch include:

  • [By Anders Bylund]

    The maker of optical networking components was off to a good start in March, but it lost all momentum when rival Finisar (NASDAQ:FNSR) reported weak earnings with mellow management comments on the state of the optical market. Finisar shares plunged 23% lower the next day, dragging Oclaro down in a 13% three-day slide.

Best Value Stocks To Invest In Right Now: Enbridge Inc(ENB)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Enbridge (NYSE:ENB) has hit a rough patch in recent years. While cash flow and its dividend have continued rising, shares have slumped about 20% since the start of 2018 and are down more than 40% from their peak in 2015. Because of that, Enbridge’s valuation has declined to a very inexpensive level, which when combined with a steady stream of dividend increases, has pushed its yield up to an eye-catching 6.7%. That high yield for a cheap price makes Enbridge look like a compelling stock to buy, especially considering all the growth it has coming down the pipeline.

  • [By Matthew DiLallo]

    Several high-yielding dividend stocks have taken it on the chin this year due to a sell-off in the stock market and rising interest rates. That one-two punch has hit pipeline stocks the hardest, with several top-notch companies tumbling by a double-digit percentage since the start of the year. Three that stand out as excellent options to consider buying now that they’re on sale are Magellan Midstream Partners (NYSE:MMP), Antero Midstream Partners (NYSE:AM), and Enbridge (NYSE:ENB).

  • [By Matthew DiLallo]

    Last November, Enbridge (NYSE:ENB) outlined its three-year strategic and financial plan. One of the key components of the Canadian pipeline giant’s strategy was selling 3 billion Canadian dollars’ ($2.3 billion as of May 9, 2018) worth of non-core assets in 2018, which would give it some of the cash needed to finance its CA$22 billion ($17 billion) expansion plan. That would enable the company to reduce debt while still growing cash flow and the dividend at a 10% compound annual rate through 2020.

  • [By Matthew DiLallo]

    Oil prices have improved dramatically over the past year as OPEC’s move to drain off the supply glut proved more successful than envisioned. That rising tide has lifted most oil stocks. However, that doesn’t mean investors have missed the boat, since many oil stocks still have ample upside. Two top ones where that’s the case are Devon Energy (NYSE:DVN) and Enbridge (NYSE:ENB).

  • [By Paul Ausick]

    Calgary-based energy infrastructure company Enbridge Inc. (NYSE: ENB) on Thursday made a nonbinding offer to acquire the approximately 17% of Spectra Energy Partners L.P. (NYSE: SEP) it does not already own in a deal that would pay unitholders of Spectra 1.0123 shares of Enbridge common stock for every common unit of Spectra they currently hold.

Best Value Stocks To Invest In Right Now: Cellect Biotechnology Ltd. (APOP)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Pacific Biosciences of California, Inc. (NASDAQ: PACB) rose 11.4 percent to $2.93 in pre-market trading.
    Check-Cap Ltd. (NASDAQ: CHEK) shares rose 6.3 percent to $4.76 in pre-market trading as the company announced the publication of CE Mark multicenter clinical study results on C-Scan® in Gut.
    Acacia Communications, Inc. (NASDAQ: ACIA) rose 6 percent to $ 35.20 in pre-market trading.
    Cellect Biotechnology Ltd. (NASDAQ: APOP) rose 6 percent to $7.60 in pre-market trading.
    Hexindai Inc. (NASDAQ: HX) rose 5.7 percent to $12.70 in pre-market trading.
    MoSys, Inc. (NASDAQ: MOSY) shares rose 5.3 percent to $2.07 in pre-market trading.
    Micron Technology, Inc. (NASDAQ: MU) rose 5 percent to $58.20 in pre-market trading after reporting a $10 billion buyback plan.
    Golden Ocean Group Limited (NASDAQ: GOGL) rose 4.1 percent to $8.63 in pre-market trading.
    MorphoSys AG (NASDAQ: MOR) rose 3.5 percent to $26.99 in pre-market trading.
    Cyren Ltd (NASDAQ: CYRN) shares rose 3.4 percent to $2.90 in pre-market trading. after reporting Q1 results.
    Box, Inc. (NYSE: BOX) rose 3.4 percent to $28.76 in pre-market trading.
    Kohl's Corporation (NYSE: KSS) shares rose 3.3 percent to $67.60 in the pre-market trading session after the company reported upbeat quarterly earnings.
    Micro Focus International plc (NYSE: MFGP) shares rose 3.1 percent to $18.40 in pre-market trading.

     

  • [By Shane Hupp]

    Cellect Biotechnology (NASDAQ: APOP) is one of 105 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Cellect Biotechnology to related companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

  • [By Stephan Byrd]

    Media stories about CELLECT BIOTECH/S (NASDAQ:APOP) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CELLECT BIOTECH/S earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.3583768207142 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.